Last week the U.S. corporation Monsanto, which holds a leading position in the global market of genetically modified organisms (GMOs), reached a licensing agreement with the Broad Institute, Cambridge, USA, on the commercial use of the innovative genome-editing technology CRISPR/Cas9 for agriculture applications. This news has led some experts to believe that Monsanto will now completely switch from producing ‘traditional’ GMOs to ‘genetically edited’ organisms, which are supposedly ‘safer and practically identical’ to their natural alternatives.
Let’s have a closer look at this technology which makes GMO supporters feel so enthusiastic and has been positioned by them as the universal panacea solving all of mankind’s problems. We will also delve deeper into some of the darker aspects of CRISPR/Cas9; the points that biotechnology lobbyists prefer not to discuss.
Comments are closed.